Applying the Principles of Disease Screening to Prostate Cancer

  • Maria A Paiva Sidra Medical and Research Center
  • Mary H. H. Ensom University of British Columbia Children's & Women's Health Centre of BC
Keywords: disease screening, prostate cancer, prostate specific antigen (PSA)


Despite prostate cancer screening programs being in place for almost two decades, their effectiveness in reducing mortality continues to be contentiously debated, resulting in polarized recommendations by various interest groups. Pharmacists are relied upon to critically appraise various types of literature, including non-drug interventions, such as disease screening programs.  It is important to understand both the purpose and principles of screening to effectively apply the literature.  We review the purpose and eight core attributes of effective screening programs with prostate cancer as the model disease state.


Author Biographies

Maria A Paiva, Sidra Medical and Research Center

Dr. Maria Paiva, BSP, PharmD, BCPS

Clinical Pharmacist, Inpatient Pharmacy

Department of Pharmacy Services

Mary H. H. Ensom, University of British Columbia Children's & Women's Health Centre of BC

Dr. Mary H. H. Ensom, BS(Pharm), PharmD, FASHP, FCCP, FCSHP, FCAHS

Professor, Faculty of Pharmaceutical Sciences, University of British Columbia

Distinguished University Scholar, University of British Columbia

Clinical Pharmacy Specialist, Children’s & Women’s Health Centre of BC



Wilson J, Junger G. Principles and practice of screening for disease. World Health Organization Public Health Papers [Internet]. 1968 [cited 2013 Oct 20]; No. 34: [about 136 p.] Available from:

Ciliska D. Screening for prostate cancer with prostate specific antigen. The Canadian Task Force on Preventative Health Care [Internet]. 2013 Jan [cited Jul 25]. Protocol No.: v2 02.0: [about 18 p.]. Available from: 2013/02/CTFPHC-Screening-for-Prostate-Cancer-protocol-v2-0.pdf?9d7bd4

BC Cancer Agency [Internet]. Vancouver: BC Cancer Agency; c1999-2013 [updated 2005 Jul 18; cited 2013 Jul 25]. Screening for cancer; [about 2 screens]. Available from: ScreeningforCancer.htm#3

Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013. [Internet]. 2013 May [cited 2013 Oct 20]; ISSN 0835-2976: [about 114 p]. Available from:

Government of Canada [Internet]. Ottawa: Human Resources and Skills Development Canada; c2013 [modified 2013 Oct 20, cited 2013 Oct 20]. Health-mortality from leading diseases; [about 3 screens]. Available from:

Hoffman R. Screening for prostate cancer [Internet]. Philadelphia (PA): Wolters Kluwer Health; c1992 [updated 2013 Jul 18; cited 2013 Jul 25]. Available from:

Djulbegovic M, Beyth R, Neuberger M, Stoffs T, Veweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ. 2010;341:c4543.

Deacon B, Abramowitz J. Fear of needles and vasovagal reactions among phlebotomy patients. J of Anxiety Disord. 2006; 20(7):946-60.

Chang S, Harshman L, Presti J. Impact of common medications on serum total prostate-specific antigen levels: analysis of the national health and nutrition examination survey. J Clin Oncol. 2010; 28(25):3951-7.

Rollins, G. PSA testing: yes, no, maybe? Clin Lab News. 2009;25(6):1-4.

Imaamura T, Yasunaga H. Economic evaluation of prostate cancer screening with prostate-specific antigen. Int J Urol. 2008;15(4):285-8.

Albin, R. The great prostate mistake. New York Times [Internet]. 2010 Mar 9 [cited 2013 Oct 20]; A:27. Available from: 10/opinion/10Ablin.html

Ilic D, O’Connor D, Green S, Wilt T. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011;107(6):882–91.

Schroder F, Hugosson M, Roobol M, Tammela T, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. NEJM. 2009;360(13):1320-8.

Andriole G, Crawford E, Grubb R 3rd, Buys S, Chia D, Church T, et al. Mortality results from a randomized prostate-cancer screening trial. NEJM. 2009;360(13):1310-9.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. NEJM. 2012;366(11):981-90.

Andriole G, Crawford E, Grubb R 3rd, Buys S, Chia D, Church T, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125-32.

Fletcher S. Screening for breast cancer: strategies and recommendations [Internet]. Philadelphia (PA): Wolters Kluwer Health; c1992 [updated 2013 Jul 31; cited 2013 Oct 26]. Available from:

Allan M, Chetner M, Donnelly B, Hagen N, Ross D, Ruether J, et al. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011;5(6):416-21.

Turini M, Redaelli A. Gramegna P, Radice D. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics. 2003;21(8):527-41.

Pederson K, Carlsson P, Varenhorst E, Lofman O, Bergland K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ. 1990:300:1041-44.

Furlan A, Kato R, Vincentini F, Cury J, Antunes A, Srougi M. Patient’s reactions to digital rectal examination of the prostate. International Braz J Urol. 2008:34(5):572-576.